WO2023241492A1 - Anticorps vhh se liant spécifiquement à cd318 humain ou son fragment de liaison à l'antigène, son procédé de préparation et son utilisation - Google Patents

Anticorps vhh se liant spécifiquement à cd318 humain ou son fragment de liaison à l'antigène, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2023241492A1
WO2023241492A1 PCT/CN2023/099572 CN2023099572W WO2023241492A1 WO 2023241492 A1 WO2023241492 A1 WO 2023241492A1 CN 2023099572 W CN2023099572 W CN 2023099572W WO 2023241492 A1 WO2023241492 A1 WO 2023241492A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence
cells
antibody
binding molecule
Prior art date
Application number
PCT/CN2023/099572
Other languages
English (en)
Chinese (zh)
Inventor
王海鹰
李靖
刘真莹
胡红明
Original Assignee
上海恒润达生生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海恒润达生生物科技股份有限公司 filed Critical 上海恒润达生生物科技股份有限公司
Publication of WO2023241492A1 publication Critical patent/WO2023241492A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to the technical field of biological immunotherapy. Specifically, it relates to an antibody that specifically binds to CD318 or an antigen-binding fragment thereof and its preparation method and application.
  • CD318, also known as CDCP1 (CUB domain-containing protein 1), encodes a highly glycosylated, single-channel type I transmembrane protein that is expressed in mesenchymal stem cells, neural stem cells, fibroblasts, and hematopoietic progenitors. expressed in cells.
  • CDCP1 consists of a large extracellular domain (ECD) containing three CUB (respectively: complement C1r/C1s, Uegf and Bmp1) domains and a short intracellular part. The protein undergoes tyrosine phosphorylation. play a role in dependence regulation.
  • CD318 is abnormally elevated in a variety of malignant tumors, including colon cancer, breast cancer, pancreatic cancer, lung cancer, kidney cancer, liver cancer, etc.
  • CD318 has been identified as a stem cell marker for benign and malignant progenitor cells.
  • Significant CD318 expression was observed in a subset of CD34CD133 leukemia cells enriched in leukemia stem cells in AML patients. Therefore, CD318 is a very promising target for tumor immunotherapy.
  • Chimeric Antigen Receptor T cell (CAR T) therapy is a new immunotherapy method that targets specific antigens on the surface of tumor cells.
  • VHH antibodies also known as nanobodies, are a type of naturally missing light chain antibody found in the peripheral blood of alpacas. The antibody only contains one heavy chain variable region (VHH) and two conventional CH2 and CH3 regions. Compared with traditional artificially modified scFv, it has the advantages of small molecular weight, easy expression, strong specificity, high affinity, weak immunogenicity to humans, and short development cycle. Combining the advantages of immunotherapy and VHH antibodies, highly efficient CAR-T therapy can be developed.
  • the invention provides a CD318-binding molecule, comprising an anti-CD318 Nanobody or an antigen-binding fragment thereof.
  • the complementarity determining region CDR of the anti-CD318 Nanobody includes CDR1, CDR2 and CDR3, wherein CDR1 includes SEQ ID NO: 1, 4, and 7.
  • CDR1 includes SEQ ID NO: 1, 4, and 7.
  • CDR2 includes the sequence shown in any one of SEQ ID NO: 2, 5, 8, 11, 14 and 17, and
  • CDR3 includes SEQ ID NO: 3, 6, Sequences shown in any of 9, 12, 15 and 18.
  • the CDRs are selected from any of the following:
  • CDR1 whose sequence is shown in SEQ ID NO:1, CDR2 whose sequence is shown in SEQ ID NO:2, and CDR3 whose sequence is shown in SEQ ID NO:3,
  • the heavy chain variable region sequence of the anti-CD318 Nanobody is set forth in any one of SEQ ID NOs: 19-24.
  • the FR1 of the anti-CD318 Nanobody can be selected from the FR1 of the VHH shown in any one of SEQ ID NO: 19-24, and the FR2 can be selected from any of SEQ ID NO: 19-24.
  • FR2 and FR3 of the VHH shown in SEQ ID NO:19-24 can be selected from the FR3 of the VHH shown in any one of SEQ ID NO:19-24, and FR4 can be selected from the FR4 of the VHH shown in any one of SEQ ID NO:19-24.
  • the CD318 binding molecule is a monovalent or multivalent Nanobody or single domain antibody, or a multispecific Nanobody comprising one, two or more anti-CD318 Nanobodies or antigen-binding fragments thereof or single domain antibodies.
  • the multivalent binding molecule or multispecific binding molecule is linked to multiple anti-CD318 Nanobodies or antigen-binding fragments thereof via a linker.
  • the linker consists of 1-15 amino acids selected from G and S.
  • the Nanobody is a camel heavy chain antibody or a cartilaginous fish heavy chain antibody.
  • the Nanobody further comprises a heavy chain constant region.
  • the heavy chain constant region is that of a camel heavy chain antibody, comprising CH2 and CH3.
  • the CH2 and CH3 are those of a human IgG Fc, such as those of an IgG1.
  • the heavy chain constant region is that of a cartilaginous fish heavy chain antibody, comprising CH1, CH2, CH3, CH4, and CH5.
  • the CD318-binding molecule according to any embodiment of the present invention is a chimeric antibody or a fully human antibody; preferably, it is a fully human antibody.
  • Another aspect of the invention provides a chimeric antigen receptor comprising an optional signal peptide sequence, a CD318 binding molecule according to any embodiment herein, a hinge region, a transmembrane region and an intracellular region.
  • the intracellular domain includes an intracellular costimulatory domain and/or an intracellular signaling domain.
  • the chimeric antigen receptor sequentially contains a signal peptide, the CD318-binding molecule described in any embodiment herein, a hinge region, a transmembrane region, and intracellular costimulation. domain and intracellular signaling domain.
  • the invention also provides nucleic acid molecules having a sequence selected from any of the following:
  • the fragment is a primer.
  • the invention also provides a nucleic acid construct comprising a nucleic acid molecule described herein.
  • the nucleic acid construct is a cloning vector, an expression vector, or an integration vector.
  • the invention also provides a host cell selected from:
  • the host cells are immune effector cells, preferably T cells.
  • the invention also provides a method for producing a CD318-binding molecule according to any embodiment herein, comprising: producing a CD318-binding molecule (e.g., a Nanobody or an antigen-binding fragment thereof, a monovalent or multivalent Nanobody or a single domain antibody, or a multispecific
  • a CD318-binding molecule e.g., a Nanobody or an antigen-binding fragment thereof, a monovalent or multivalent Nanobody or a single domain antibody, or a multispecific
  • the host cells described herein are cultured under the conditions of specific Nanobodies or single domain antibodies), and the CD318 binding molecules are optionally purified from the culture.
  • the present invention also provides a pharmaceutical composition, comprising the CD318 binding molecule, nucleic acid molecule, nucleic acid construct or host cell described in any embodiment herein, and pharmaceutically acceptable excipients.
  • the pharmaceutical composition is used to treat a disease or condition associated with CD318 expression.
  • the present invention also provides the use of the CD318 binding molecule, chimeric antigen receptor, nucleic acid molecule, nucleic acid construct or host cell of any embodiment herein for producing activated immune cells (eg, T cells).
  • activated immune cells eg, T cells
  • the present invention also provides the use of the CD318 binding molecule, chimeric antigen receptor, nucleic acid molecule, nucleic acid construct or host cell according to any embodiment herein in the preparation of a medicament for preventing or treating diseases or conditions related to CD318 expression.
  • the disease or condition is selected from one or more of the following: breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer, kidney cancer, and colorectal cancer.
  • the present invention also provides a method for treating or preventing diseases or conditions related to CD318 expression, which method includes administering to a patient in need a therapeutically effective amount of the CD318-binding molecule or host cell according to any embodiment of the present invention, or the present invention.
  • the present invention also provides a kit for detecting CD318, which is used, for example, to evaluate drug treatment effects or diagnose cancer.
  • the kit includes the CD318-binding molecule, nucleic acid molecule, nucleic acid construct or host cell described in any embodiment of this document.
  • the kit further includes a reagent for detecting binding of CD318 to the CD318 binding molecule.
  • the bound reagent is detected, for example, by enzyme-linked immunoassay.
  • the reagent that detects binding is a detectable label, such as biotin, that can be linked to a CD318 binding molecule.
  • the detectable label is connected to the CD318 binding molecule or is present separately in the kit.
  • the present invention also provides a non-diagnostic method for detecting the presence of CD318 in a sample.
  • the method includes: incubating the sample with the CD318-binding molecule described in any embodiment of this document, and detecting the binding of CD318 to the CD318-binding molecule, This determines the presence of CD318 in the sample.
  • the detection is an enzyme-linked immunoreaction assay.
  • the present invention also provides the use of the CD318-binding molecule described in any embodiment herein in the preparation of a kit for detecting CD318 in a sample, evaluating the effect of drug treatment, or diagnosing cancer.
  • the present invention provides a new Nanobody that specifically recognizes CD318 and CAR-modified cells containing the antibody.
  • the antibody and cells have good therapeutic effects targeting CD318 and provide new treatments for diseases related to CD318 expression. or ways to improve.
  • Figure 1 shows the SDS electrophoresis pattern of recombinant human CD318-avi-his antigen protein.
  • Figure 2 is a schematic diagram of different cloned CD318 CARs.
  • Figure 3 shows the CAR expression positive rate of CD318 CAR-T cells of different clones.
  • Figure 4 shows the expression of CD107a in CD318 CAR-T cells of different clones.
  • Figure 5 shows the INF ⁇ secretion of CD318 CAR-T cells of different clones when the effect-to-target ratio is 10:1.
  • Figure 6 shows the INF ⁇ secretion of CD318 CAR-T cells of different clones when the effect-to-target ratio is 2:1.
  • Figure 7 shows the IL-2 secretion of CD318 CAR-T cells of different clones when the effect-to-target ratio is 10:1.
  • Figure 8 shows the IL-2 secretion of CD318 CAR-T cells of different clones when the effect-to-target ratio is 2:1.
  • Figure 9 shows the results of the killing experiment of different clones of CD318 CAR-T cells on target cells.
  • Figure 10 shows the results of the killing experiment of different clones of CD318 CAR-T cells on target cells.
  • the present invention uses CD318 protein to immunize alpacas to obtain a high-quality single domain antibody gene library. Phage display technology was then used to screen the antibody gene library, thereby obtaining a CD318-specific single domain antibody gene. This gene is then transferred into mammalian cells, thereby obtaining an antibody strain with high specificity that can be expressed efficiently in mammalian cells.
  • the antibody or its antigen-binding fragment has good safety and targeting properties, and can specifically bind to the extracellular domain of human CD318.
  • the present invention also provides chimeric antigen receptors (CARs) containing the Nanobodies.
  • CARs chimeric antigen receptors
  • a vector containing the coding sequence of the CAR to infect immune cells, immune effector cells with significant killing ability against tumor cells overexpressing CD318 can be obtained.
  • the immune effector cells can be used to treat or improve diseases related to CD318 expression, thereby This lays the foundation for the treatment of CD318-positive tumors.
  • CD318-binding molecules are proteins that specifically bind to CD318, including but not limited to antibodies, heavy chain antibodies, Nanobodies or their antigen-binding fragments.
  • antibody includes monoclonal antibodies (including full-length antibodies having an immunoglobulin Fc region), antibody compositions with multiple epitope specificities, multispecific antibodies (e.g., bispecific antibodies), diabodies and single-chain molecules, as well as antibody fragments, especially antigen-binding fragments, such as Fab, F(ab')2, Fd and Fv.
  • antibody and “immunoglobulin” are used interchangeably.
  • Antibodies contain the basic 4-chain antibody unit, which is a heterotetrameric glycoprotein composed of two identical light chains (L) and two identical heavy chains (H). Each heavy chain has a variable domain (VH) at the N-terminus, followed by three (for each alpha and gamma chain, CH1, CH2 and CH3) and four (for the ⁇ and epsilon isoforms, CH1, CH2, CH3 and CH4) constant domains (CH) and a hinge region (Hinge) located between the CH1 and CH2 domains. Each light chain has a variable domain (VL) at the N-terminus, followed by a constant domain (CL) at its other end. Pairs of VH and VL together form an antigen-binding site.
  • VH variable domain
  • CL constant domain
  • Light chains from any vertebrate species can be assigned to one of two distinct types called kappa and lambda, based on their constant domain amino acid sequence.
  • the gamma and alpha classes can be further divided into subclasses based on relatively small differences in CH sequence and function, for example humans express the following subclasses: IgG1, IgG2A, IgG2B, IgG3, IgG4, IgA1 and IgA2.
  • Heavy chain antibodies as used herein are antibodies derived from camelids or cartilaginous fishes. Compared with the above 4-chain antibodies, the heavy chain antibody lacks the light chain and heavy chain constant region 1 (CH1), and only contains 2 heavy chains composed of variable regions (VHH) and other constant regions. The variable region has a hinge-like structure. connected to the constant region. Each heavy chain of camelid heavy chain antibodies contains 1 variable region (VHH) and 2 constant regions (CH2 and CH3), and each heavy chain of chondrichthyan heavy chain antibodies contains 1 variable region and 5 constant regions. Constant region (CH1-CH5).
  • Antigen-binding fragments of heavy chain antibodies include VHH and single-chain heavy chain antibodies.
  • the heavy chain antibody can have CH2 and CH3 of human IgG Fc by fusion to the constant region of human IgG Fc.
  • single domain antibody As used herein, the terms “single domain antibody”, “anti-CD318 single domain antibody”, “heavy chain variable region domain of a heavy chain antibody” and “VHH” are used interchangeably and all refer to specific recognition and binding to CD318 of single domain antibodies.
  • Single domain antibodies are the variable regions of heavy chain antibodies. Typically, single domain antibodies contain three CDRs and four FRs.
  • the single domain antibody of the present invention has CDR1 shown in SEQ ID NO:1, CDR2 shown in SEQ ID NO:2, and CDR3 shown in SEQ ID NO:3; or has CDR3 shown in SEQ ID NO:4 CDR1, CDR2 shown in SEQ ID NO:5, and CDR3 shown in SEQ ID NO:6; or having CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and SEQ ID NO : CDR3 shown in SEQ ID NO: 9; or having CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; or having CDR3 shown in SEQ ID NO: 13 CDR1, CDR2 represented by SEQ ID NO:14, and CDR3 represented by SEQ ID NO:15; or having CDR1 represented by SEQ ID NO:16, CDR2 represented by SEQ ID NO:17, and SEQ ID NO: CDR3 shown in 18.
  • Single domain antibodies are the smallest functional antigen-binding fragments. Usually, after obtaining an antibody that naturally lacks the light chain and heavy chain constant region 1 (CH1), the variable region of the antibody heavy chain is cloned to construct a single-domain antibody consisting of only one heavy chain variable region.
  • CH1 light chain and heavy chain constant region 1
  • “Nanobody” refers to an antibody containing a VHH as described herein. It can be a heavy chain antibody as described above, or a multivalent or multispecific antibody containing multiple VHHs, or it can be obtained by recombining VHH and antibody Fc (such as CH2 and CH3 or CH2, CH3 and CH4) Recombinant antibodies. Binding molecules containing two or more single domain antibodies are multivalent single domain antibodies; binding molecules containing two or more single domain antibodies with different specificities are multispecific single domain antibodies. Multivalent single domain antibodies or multispecific single domain antibodies connect multiple single domain antibodies via a linker. The linker usually consists of 1-15 amino acids selected from G and S.
  • heavy chain antibodies and antibodies are intended to distinguish different combinations of antibodies. Due to the structural similarity between the two, the following structural descriptions of antibodies are applicable to heavy chain antibodies in addition to the light chain.
  • variable region refers to the amino-terminal domain of the heavy or light chain of the antibody.
  • variable domains of the heavy and light chains may be referred to as "VH” and “VL” respectively. These domains are typically the most variable parts of the antibody (relative to other antibodies of the same type) and contain the antigen-binding site.
  • variable refers to the situation where certain segments of the variable domain vary widely among antibody sequences. Variable domains mediate antigen binding and define the specificity of a particular antibody for its particular antigen. However, variability is not evenly distributed across all amino acids spanned by the variable domain. Instead, it is concentrated in three segments called hypervariable regions (HVRs) (found in both light and heavy chain variable domains), namely HCDR1, HCDR2, and HCDR3 (heavy chain variable domains), respectively.
  • HVRs hypervariable regions
  • chain antibodies can be abbreviated as CDR1, CDR2, CDR3
  • the more highly conserved part of the variable domain is called the framework region (FR).
  • variable domains of the native heavy and light chains each contain four FR regions (FR1, FR2, FR3, and FR4), which mostly adopt a ⁇ -sheet conformation by forming loop connections and in some cases forming a ⁇ -sheet structure Part of the three HVR connections.
  • the HVRs in each chain are held in close proximity by the FR region and together with the HVRs of the other chain contribute to the formation of the antibody's antigen-binding site.
  • the structure of the light chain variable region is FR1-LCDR1-FR2-LCDR2-FR3-LCDR3-FR4
  • the structure of the heavy chain variable region is FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4.
  • the constant domain is not directly involved in binding of the antibody to the antigen, but exhibits a variety of effector functions, such as the involvement of the antibody in antibody-dependent cell-mediated cytotoxicity.
  • effector functions such as the involvement of the antibody in antibody-dependent cell-mediated cytotoxicity.
  • Fc region (crystallizable fragment region) or “Fc domain” or “Fc” refers to the C-terminal region of an antibody heavy chain that mediates binding of immunoglobulins to host tissues or factors, including those located in the immune system Binding to Fc receptors on various cells (e.g., effector cells) or to the first component (C1q) of the classical complement system.
  • the Fc region is composed of two identical protein fragments from the CH2 and CH3 domains of the two heavy chains of the antibody; the Fc regions of IgM and IgE are present in each polypeptide chain. Contains three heavy chain constant domains (CH domains 2-4).
  • an Fc region of an immunoglobulin heavy chain is generally defined as the sequence segment from the amino acid residue at position C226 or P230 of the heavy chain to the carboxyl terminus, where this numbering is according to the EU index, as in Same in Kabat.
  • an Fc region may be a native sequence Fc or a variant Fc.
  • Antibody fragment includes a portion of an intact antibody, preferably the antigen-binding region and/or variable region of an intact antibody.
  • the antibody fragment is preferably an antigen-binding fragment of an antibody.
  • antibody fragments include Fab, Fab', F(ab'), F(ab')2, Fd, and Fv fragments, disulfide-linked Fv; diabodies; linear antibodies; single chain antibody molecules; scFv-Fc fragments; multispecific antibodies formed from antibody fragments; and any fragment that should be capable of increasing half-life, either by chemical modification or by incorporation into liposomes.
  • Antigen-binding fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies, and expression of host cells containing the antigen-binding fragments.
  • Fv is the smallest antibody fragment containing intact antigen recognition and binding sites. This fragment consists of a dimer of a heavy chain variable domain and a light chain variable domain in tight, non-covalent association. Six hypervariable loops (3 loops each in the heavy and light chains) protrude from the fold of these two domains, contributing amino acid residues for antigen binding and conferring antigen-binding specificity to the antibody. However, even a single variable domain (or half an Fv containing only three HVRs specific for the antigen) has the ability to recognize and bind antigen, albeit with lower affinity than the full binding site.
  • Single-chain Fv also abbreviated as “sFv” or “scFv”
  • sFv is an antibody fragment containing the VH and VL domains of an antibody linked into a polypeptide chain.
  • the sFv polypeptide also contains a polypeptide linker between the VH and VL domains so that the sFv forms the desired antigen-binding structure.
  • the scFv is the VHH.
  • the term "monoclonal antibody” refers to an antibody obtained from a population of antibodies that are essentially homogeneous, i.e., except for possible naturally occurring mutations and/or post-translational modifications that may be present in small amounts (e.g. isomerization, amidation ), the individual antibodies that make up the population are identical. Monoclonal antibodies are highly specific and target a single antigenic site. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
  • monoclonal antibodies are synthesized by hybridoma culture and are not contaminated by other immunoglobulins.
  • the modifier "monoclonal" indicates that the antibody is derived from a substantially homogeneous population of antibodies and should not be construed as requiring that the antibody be produced by any particular method.
  • monoclonal antibodies to be used in accordance with the present invention can be produced by a variety of techniques, including, for example, hybridoma methods, phage display methods, recombinant DNA methods, and methods for producing antibodies containing part or all of a human immunoglobulin locus or encoding a human immunoglobulin locus. Techniques and single-cell sequencing methods for producing human or human-like antibodies from animals using immunoglobulin sequence genes.
  • Monoclonal antibodies are also included herein as "chimeric" antibodies in which a portion of the heavy chain and/or light chain is derived from a specific species or belongs to a specific The corresponding sequence in an antibody of an antibody class or subclass is identical or homologous, and the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, and such Fragments of antibodies as long as they exhibit the desired biological activity.
  • “Humanized” forms of non-human (eg, murine) antibodies refer to chimeric antibodies that contain minimally sequence derived from a non-human immunoglobulin.
  • a “humanized antibody” generally refers to a non-human antibody in which the variable domain framework regions are exchanged with sequences found in human antibodies.
  • the entire antibody except for the CDRs
  • CDRs some or all of which are encoded by nucleic acids derived from non-human organisms, are grafted into the beta-sheet backbone of human antibody variable regions to produce antibodies whose specificity is determined by the grafted CDRs.
  • Methods for producing such antibodies are well known in the art, for example using mice with genetically engineered immune systems.
  • antibodies, single domain antibodies, heavy chain antibodies, etc. all include humanized variants of each of the antibodies.
  • Human antibody refers to an antibody that has an amino acid sequence corresponding to that of an antibody produced by a human and/or is produced using any of the techniques disclosed herein for producing human antibodies. This definition of human antibodies specifically excludes humanized antibodies containing non-human antigen-binding residues. Human antibodies can be generated using a variety of techniques known in the art, including phage display libraries.
  • the invention also provides Nanobodies, heavy chain antibodies, antibodies or antigen-binding fragments thereof that bind the same epitope on human CD318 as the antigen-joining region of any anti-CD318 Nanobody of the invention (e.g., single domain antibody VHH ), that is, a Nanobody, heavy chain antibody, antibody or antigen-binding fragment thereof that can cross-compete with the antigen-binding region of any Nanobody of the present invention for binding to CD318.
  • any anti-CD318 Nanobody of the invention e.g., single domain antibody VHH
  • the anti-CD318 single domain antibody has CDR1 shown in SEQ ID NO:1, CDR2 shown in SEQ ID NO:2, and CDR3 shown in SEQ ID NO:3; or has CDR3 shown in SEQ ID NO:4 CDR1, CDR2 shown in SEQ ID NO:5, and CDR3 shown in SEQ ID NO:6; or having CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and SEQ ID NO : CDR3 shown in SEQ ID NO: 9; or having CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; or having CDR3 shown in SEQ ID NO: 13 CDR1, CDR2 represented by SEQ ID NO:14, and CDR3 represented by SEQ ID NO:15; or having CDR1 represented by SEQ ID NO:16, CDR2 represented by SEQ ID NO:17, and SEQ ID NO: CDR3 shown in 18.
  • FR1, FR2, FR3 and FR4 of the anti-CD318 single domain antibody described herein can be independently selected from FR1, FR2, FR3 and FR4 of the single domain antibody shown in any one of SEQ ID NO: 19-24.
  • the amino acid sequence of the anti-CD318 single domain antibody is as shown in any one of SEQ ID NO: 19-24.
  • a Nanobody is a heavy chain antibody comprising a single domain antibody as described herein.
  • the heavy chain constant region may be that of a camel heavy chain antibody, including CH2 and CH3.
  • the antibody constant region is derived from: the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD, more preferably derived from any one of IgG1, IgG2, IgG3, IgG4 or's constant region.
  • the heavy chain constant region is CH2 and CH3 of a human IgG Fc, e.g., CH2 and CH3 of IgG1.
  • the CD318 binding molecules described herein can be monovalent or multivalent Nanobodies or single domain antibodies, or multispecific Nanobodies or single domain antibodies, including one, two or more anti-CD318 Nanobodies or single domain antibodies described herein.
  • Multispecificity can be against CD318 and another antigen, or it can be against two different epitopes of CD318.
  • the invention also includes such antibody derivatives and analogs.
  • “Derivatives” and “analogues” refer to polypeptides that substantially retain the same biological function or activity of the antibodies of the invention.
  • Derivatives or analogs of the present invention may be (i) a polypeptide having substituent groups in one or more amino acid residues, or (ii) a mature polypeptide combined with another compound (such as a compound that extends the half-life of the polypeptide, such as polyethylene glycol).
  • polypeptide formed by fusion of an additional amino acid sequence to this polypeptide sequence such as a leader sequence or secretion sequence or a sequence used to purify this polypeptide or a protein sequence, or with a 6His tag fusion protein formed.
  • those skilled in the art can change one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids to obtain variants of the antibody or functional fragment sequence thereof.
  • These variants include (but are not limited to): deletion of one or more (usually 1-50, preferably 1-30, more preferably 1-20, optimally 1-10) amino acids , insertion and/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and/or N-terminus.
  • conservative substitutions with amino acids with similar or similar properties generally do not change the function of the protein. For example, amino acids with similar properties are substituted in the FR and/or Fc region.
  • amino acid residues that are subject to conservative substitutions are well known in the art. Such substituted amino acid residues may or may not be encoded by the genetic code. As another example, adding one or more amino acids to the C-terminus and/or N-terminus usually does not change the function of the protein. They are all considered to be included in the scope of protection of the present invention.
  • Variant forms of the antibodies described herein include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, hybridization to the DNA encoding the antibody of the invention under high or low stringency conditions Proteins encoded by DNA, and polypeptides or proteins obtained using antiserum against the antibodies of the present invention.
  • the sequence of a variant described herein may be at least 95%, 96%, 97%, 98% or 99% identical to the sequence from which it is derived.
  • the sequence identity described in the present invention can be measured using sequence analysis software.
  • the computer program BLAST uses default parameters, especially BLASTP or TBLASTN.
  • the present invention also includes those molecules having antibody heavy chain variable regions with CDRs as long as the CDRs are more than 90% (preferably more than 95%, optimally more than 98%) homologous to the CDRs identified herein .
  • the antibodies of the present invention can be prepared using conventional methods in the art, such as hybridoma technology.
  • Nanobodies of the present invention can be prepared using conventional methods in the art, such as phage display technology, which is well known in the art.
  • the antibodies or Nanobodies of the invention can be expressed in other cell lines.
  • Suitable mammalian host cells can be transformed with sequences encoding the antibodies of the invention, and the host cells can then be cultured and the antibodies purified. Transformation can be performed using any known method, including, for example, packaging the polynucleotide in a virus (or viral vector) and transducing the host cell with the virus (or vector). The transformation procedure used depends on the host being transformed.
  • Methods for introducing heterologous polynucleotides into mammalian cells include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation , encapsulating polynucleotides in liposomes and microinjecting DNA directly into the nucleus, etc.
  • Mammalian cell lines that can be used as hosts for expression are well known in the art and include, but are not limited to, a variety of immortalized cell lines available from the American Type Culture Collection (ATCC), including, but not limited to, Chinese Hamster Ovary (CHO) ) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (eg, HepG2), etc.
  • ATCC American Type Culture Collection
  • the present invention also provides a chimeric antigen receptor (CAR) targeting CD318.
  • the CAR contains an optional signal peptide sequence, an antigen recognition region, namely the anti-CD318 binding molecule described herein, a hinge region, a transmembrane region and an intracellular region.
  • the intracellular region includes one or more intracellular costimulatory domains and/or one or more intracellular signaling domains.
  • the "hinge region”, “transmembrane region” and “intracellular region” in this article can all be selected from the sequences of the hinge region, transmembrane region and intracellular region in known CAR-T technology.
  • a signal peptide is a peptide sequence that targets a polypeptide to a desired location in a cell.
  • the signal peptide targets the polypeptide to the secretory pathway of the cell and will allow the polypeptide to integrate and anchor into the lipid bilayer; the signal peptide may also be a membrane-localized signal peptide.
  • Exemplary signal peptides such as CD8 signal peptide, CD28 signal peptide, CD4 signal peptide or light chain signal peptide, the sequences of which are within the knowledge of those skilled in the art.
  • the CD8 signal peptide suitable for the present invention can be various human CD8 signal peptide sequences commonly used for CAR in the art.
  • the amino acid sequence of the CD8 signal peptide includes the sequence shown in SEQ ID NO: 25.
  • the hinge region of the chimeric antigen receptor is located between the extracellular antigen-binding region and the transmembrane region.
  • the hinge region is a segment of amino acids that usually exists between two domains of a protein and can allow for the flexibility of the protein and the separation of the two domains. move relative to each other.
  • the hinge region may be of a naturally occurring protein Hinge area or part thereof.
  • Hinge regions of antibodies such as IgG, IgA, IgM, IgE or IgD antibodies may also be used in the chimeric antigen receptors described herein.
  • Non-naturally occurring peptides may also be used as hinge regions of the chimeric antigen receptors described herein.
  • the hinge region of the CAR is selected from the group consisting of CD8 ⁇ hinge region, IgD hinge region, IgG1 Fc CH2CH3 hinge region or IgG4 Fc CH2CH3 hinge region, the sequences of which are within the knowledge of those skilled in the art.
  • the CD8 ⁇ hinge region suitable for the present invention can be various human CD8 ⁇ hinge region sequences commonly used for CAR in the art.
  • the human CD8 alpha hinge region comprises the sequence set forth in SEQ ID NO:26.
  • the transmembrane region of a chimeric antigen receptor can form an alpha helix, a complex of more than one alpha helix, a beta barrel, or any other stable structure capable of spanning the cellular phospholipid bilayer.
  • the transmembrane region may be of natural or synthetic origin.
  • the transmembrane region may be selected from those of the following proteins: CD3 ⁇ , CD4, CD5, CD8 ⁇ , CD9, CD16, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, T cell receptor ⁇ , ⁇ or ⁇ chain of the body.
  • the human CD8 ⁇ transmembrane region suitable for the present invention can be various human CD8 ⁇ transmembrane region sequences commonly used for CAR in the art.
  • the amino acid sequence of the human CD8 ⁇ transmembrane region includes the sequence shown in SEQ ID NO: 27.
  • the intracellular signaling domain (or intracellular signaling domain) is responsible for the activation of at least one normal effector function of the immune effector cell expressing the chimeric antigen receptor.
  • the effector function of a T cell may be cytolytic activity or auxiliary activity, including secretion of cytokines.
  • cytolytic activity or auxiliary activity, including secretion of cytokines.
  • auxiliary activity including secretion of cytokines.
  • an intracellular signaling domain includes any truncated form of an intracellular signaling domain that is sufficient to transduce an effector function signal.
  • the intracellular signaling domain of the CAR can be selected as needed, including but not limited to those derived from at least one of CD3 ⁇ , FcR ⁇ (FCER1G), FcR ⁇ (Fc ⁇ Rib), CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD5, CD22, CD79a, CD79b and CD66d Intracellular signaling domain.
  • the intracellular signal region is derived from the human CD3 ⁇ intracellular signal region.
  • the human CD3 ⁇ intracellular signal region has the amino acid sequence shown in SEQ ID NO: 29.
  • costimulatory domain may be the cytoplasmic portion of a costimulatory molecule.
  • costimulatory molecule refers to an associated binding partner on an immune cell, such as a T cell, that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the immune cell, such as, but not limited to, proliferation and survival. .
  • Suitable intracellular costimulatory domains can be selected as needed, including intracellular domains with costimulatory signaling molecules, such as those derived from 4-1BB, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54, CD83, OX40 , CD137, CD134, CD150, CD152, CD223, CD270, PD-L2, PD-L1, CD278, DAP10, LAT, NKD2C, SLP76, TRIM, Fc ⁇ RI ⁇ , MyD88, and at least one of the intracellular domains of 41BBL.
  • the amino acid sequence of the 4-1BB costimulatory domain comprises the sequence set forth in SEQ ID NO: 28.
  • the above-mentioned parts that form the chimeric antigen receptor of the present invention interact with each other.
  • the linkage can be direct or can be linked via a linker sequence.
  • the linker sequence may be one well known in the art and suitable for use with antibodies, such as a G and S-containing linker sequence.
  • linkers typically contain one or more repeating motifs.
  • the motif may be GGGS, GGGGS, SSSSG, GSGSA, and GGSGG.
  • the motifs are contiguous in the linker sequence, with no intervening amino acid residues between repeats.
  • Linker sequences can contain 1, 2, 3, 4 or 5 repeating motifs.
  • the length of the linker can be 3 to 25 amino acid residues, such as 3 to 15, 5 to 15, or 10 to 20 amino acid residues.
  • the linker sequence is a polyglycine linker sequence.
  • the number of glycines in the linker sequence is not particularly limited, but is usually 2 to 20, such as 2 to 15, 2 to 10, or 2 to 8.
  • the linker can also contain other known amino acid residues, such as alanine (A), leucine (L), threonine (T), glutamic acid (E), phenylalanine Acid (F), arginine (R), glutamine (Q), etc.
  • the linker sequence is a (GGGGS)n linkage, where n is an integer from 1 to 5.
  • the CAR contains CD8 signal peptide, anti-CD318 Nanobody or antigen-binding fragment thereof described herein, CD8 ⁇ hinge region, CD8 ⁇ transmembrane region, 4-1BB costimulatory domain, in sequence from N-terminus to C-terminus. CD3 ⁇ intracellular signaling domain.
  • an exemplary CAR having the above structure is as shown in any of SEQ ID NOs: 30-35.
  • the amino terminus or carboxyl terminus of the CAR of the present invention may also contain one or more polypeptide fragments as protein tags.
  • Any suitable tag may be used for this article.
  • the tags may be FLAG, HA, HA1, c-Myc, Poly-His, Poly-Arg, Strep-TagII, AU1, EE, T7, 4A6, ⁇ , B, gE and Ty1. These tags can be used to purify proteins.
  • the antigen recognition region in the CAR of the present invention can be a variant of the aforementioned anti-CD318 Nanobody or its functional fragment sequence.
  • other parts of the CAR can also undergo sequence changes, and the resulting mutant has at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97% sequence identity with the CAR and retains the sequence identity.
  • Biological activity of CAR (such as activated T cells). Sequence identity between two aligned sequences can be calculated using, for example, NCBI's BLASTp.
  • Mutants also include amino acid sequences that have one or several mutations (insertions, deletions, or substitutions) in the amino acid sequence of the CAR described in any embodiment while still retaining the biological activity of the CAR.
  • the number of mutations usually refers to within 1-10, such as 1-8, 1-5 or 1-3.
  • Substitutions are preferably conservative substitutions.
  • conservative substitutions with amino acids with similar or similar properties generally do not change the function of the protein or polypeptide.
  • amino acids with similar or similar properties include, for example, families of amino acid residues with similar side chains.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • amino acids with acidic side chains chain amino acids (e.g., aspartic acid, glutamic acid)
  • amino acids with uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine amino acids
  • amino acids with non-polar side chains such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • Amino acids with ⁇ -branched side chains eg threonine, valine, isoleucine
  • amino acids with aromatic side chains eg tyrosine, phenylalanine, tryptophan, histidine
  • the invention also provides polynucleotides encoding the above-mentioned antibodies or CARs.
  • the polynucleotides of the invention may be in DNA form or RNA form. Forms of DNA include cDNA, genomic DNA, or synthetic DNA. DNA can be single-stranded or double-stranded. DNA can be a coding strand or a non-coding strand.
  • the present invention also encompasses degenerate variants of the polynucleotide sequence encoding the fusion protein, ie, nucleotide sequences encoding the same amino acid sequence but with different nucleotide sequences.
  • the present invention also relates to polynucleotides that hybridize to the above-mentioned polynucleotide sequences and have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences.
  • the invention particularly relates to polynucleotides that hybridize under stringent conditions to the polynucleotides of the invention.
  • stringent conditions refer to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2 ⁇ SSC, 0.1% SDS, 60°C; or (2) adding water during hybridization There are denaturants, such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll, 42°C, etc.; or (3) only the identity between the two sequences is at least 90%, more It is best when hybridization occurs only when the ratio is above 95%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
  • the full-length nucleotide sequence of the antibody of the present invention or its fragment can usually be obtained by PCR amplification, recombinant or artificial synthesis.
  • one A feasible method is to use artificial synthesis to synthesize the relevant sequences, especially when the fragment length is short. Often, fragments with long sequences are obtained by first synthesizing multiple small fragments and then ligating them.
  • the coding sequence of the heavy chain and the expression tag (such as 6His) can also be fused together to form a fusion protein.
  • the sequence of the CAR can also be obtained as above.
  • the sequences of each part of the CAR (signal peptide, antigen recognition region, hinge region, transmembrane region or intracellular region) can be obtained as above and then connected to obtain the full length of the CAR.
  • Biomolecules (nucleic acids, proteins, etc.) involved in the present invention include biomolecules in isolated form.
  • the DNA sequence encoding the protein of the present invention (or its fragments, or its derivatives) can be obtained entirely through chemical synthesis.
  • the DNA sequence can then be introduced into a variety of existing DNA molecules (or vectors) and cells known in the art.
  • mutations can also be introduced into the protein sequence of the invention through chemical synthesis.
  • Each part of the CAR can be cloned sequentially into the vector or can be integrated into the full-length CAR and then cloned.
  • the present invention also relates to nucleic acid constructs containing the polynucleotide sequences described herein, and one or more regulatory sequences operably linked to these sequences.
  • the polynucleotide sequences of the invention can be manipulated in various ways to ensure the expression of the antibody or CAR. Before inserting the nucleic acid construct into the vector, the nucleic acid construct can be manipulated according to the differences or requirements of the expression vector. Techniques for altering polynucleotide sequences using recombinant DNA methods are known in the art.
  • the control sequence may be a suitable promoter sequence.
  • the promoter sequence is usually operably linked to the coding sequence of the protein to be expressed.
  • the promoter can be any nucleotide sequence that exhibits transcriptional activity in the host cell of choice, including mutant, truncated, and hybrid promoters, and can be derived from genes encoding extracellular genes that are homologous or heterologous to the host cell. or genetic acquisition of intracellular polypeptides.
  • An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence.
  • CMV immediate early cytomegalovirus
  • the promoter sequence is a strong constitutive promoter sequence capable of driving high-level expression of any polynucleotide sequence operably linked thereto.
  • EF-1 ⁇ elongation growth factor-1 ⁇
  • SV40 simian virus 40
  • MMTV mouse mammary tumor virus
  • HSV human immunodeficiency virus
  • LTR long terminal repeat
  • MoMuLV avian leukemia virus promoter
  • Epstein-Barr virus immediate early promoter Epstein-Barr virus immediate early promoter
  • Ruth's sarcoma virus promoter and human gene promoters such as but not limited to actin promoter, myosin promoter, heme promoter and creatine kinase promoter.
  • inducible promoters may also be considered.
  • an inducible promoter provides a molecular switch capable of turning on expression of a polynucleotide sequence operably linked to the inducible promoter when expression is required and turning off expression when expression is undesirable.
  • inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
  • the control sequence may also be a suitable transcription terminator sequence, a sequence recognized by the host cell to terminate transcription.
  • the terminator sequence is operably linked to the 3' end of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in the host cell of choice can be used in the present invention.
  • the regulatory sequence may also be a suitable leader sequence, an untranslated region of the mRNA important for translation by the host cell. The leader sequence is operably linked to the 5' end of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in the host cell of choice can be used in the present invention.
  • the nucleic acid construct is a vector, such as a cloning vector, an expression vector, and an integration vector.
  • Expression of a polynucleotide sequence of the invention is generally accomplished by operably linking the polynucleotide sequence of the invention to an expression vector.
  • Typical cloning vectors contain transcriptional and translational terminators, initiation sequences, and promoters that can be used to regulate expression of the desired nucleic acid sequence.
  • Integration vectors contain components that integrate target sequences into the cellular genome. These vectors can be used to transform appropriate host cells to enable expression of the protein.
  • Vectors typically contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences.
  • the sequences (collectively referred to in certain embodiments as “flanking sequences”) generally include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, a donor-containing sequence and acceptor splice site, a sequence encoding a leader for secretion of the polypeptide, a ribosome binding site, a polyadenylation sequence, and a polylinker for insertion of nucleic acid encoding the antibody to be expressed. area and optional marker elements.
  • the type of vector is not limited, for example, plasmids, phagemids, phage derivatives, animal viruses, and cosmids, and may vary depending on the host cell to be introduced.
  • Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals.
  • Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses.
  • the vector introduced into the cell may also contain either or both a selectable marker gene or a reporter gene to facilitate identification of the population of cells sought to be transfected or infected by the viral vector. Identification and selection of expressing cells.
  • Host cells suitable for introducing the nucleic acid constructs described herein can be prokaryotic cells, such as bacterial cells; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells, especially immune cells, Immune effector cells are preferred.
  • prokaryotic cells such as bacterial cells
  • lower eukaryotic cells such as yeast cells
  • higher eukaryotic cells such as mammalian cells, especially immune cells
  • Immune effector cells are preferred.
  • Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS7, 293 cells, etc.
  • Immuno effector cells are immune cells that perform immune effector functions.
  • the immune effector cells express at least Fc ⁇ RIII and perform ADCC effector functions.
  • Examples of immune effector cells that mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells, neutrophils, and eosinophils.
  • PBMC peripheral blood mononuclear cells
  • NK natural killer
  • monocytes cytotoxic T cells
  • neutrophils neutrophils
  • eosinophils eosinophils.
  • the immune effector cells are selected from: at least one of immune cells cultured and differentiated from pluripotent stem cells or embryonic stem cells, T lymphocytes, NK cells, peripheral blood mononuclear cells (PBMC) and hematopoietic stem cells. More preferably, the immune effector cells are T lymphocytes (the same as T cells).
  • T cells can be CD4+/CD8-, CD4-/CD8+, CD4+/CD8+, CD4-/CD8-, or combinations thereof.
  • T cells produce IL-2, IFN, and/or TNF when expressing chimeric antigen receptors and binding to target cells.
  • CD8+ T cells lyse antigen-specific target cells when expressing chimeric antigen receptors and binding to target cells.
  • T cells suitable for use in the present invention can be various types of T cells from various sources.
  • T cells can be derived from PBMCs of patients with malignant solid tumors, such as pancreatic cancer.
  • T cells after T cells are obtained, they can be first stimulated and activated with an appropriate amount (for example, 30-80ng/ml, such as 50ng/ml) of CD3 antibodies, and then containing an appropriate amount (for example, 30-80IU/ml, such as 50ng/ml) of CD3 antibody for activation. 50IU/ml) IL2 medium for culture and use.
  • nucleic acids or vectors into mammalian cells
  • the vectors may be introduced into the cells by physical, chemical, or biological means.
  • the host is a prokaryotic organism such as E. coli
  • competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method.
  • the steps used are well known in the art.
  • the host is a eukaryotic organism
  • the following DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
  • transduced or transfected immune effector cells are propagated ex vivo following introduction of nucleic acid or vector.
  • the obtained transformants can be cultured using conventional methods to express the antibody or CAR encoded by the gene of the present invention.
  • the medium used in culture can be selected from various conventional media. Cultivate under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced using an appropriate method (such as temperature shift or chemical induction), and the cells are cultured for a further period of time.
  • the polypeptide in the above method can be expressed within the cell, on the cell membrane, or secreted outside the cell.
  • the recombinant protein can be isolated and purified by various separation methods utilizing its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitating agents (salting out method), centrifugation, osmotic sterilization, ultratreatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid phases Chromatographic techniques and combinations of these methods.
  • Nanobodies that could bind CD318.
  • the inventors constructed CAR and CAR-T cells. After experimental verification at the cell level, the CAR-T has strong immune function, better CD107a expression, IFN- ⁇ and IL-2 secretion, and resistance to The specific killing function of target cells has significant efficacy in vivo.
  • All aspects of the antibodies, CARs, coding sequences, nucleic acid constructs, and cells described herein can be used to prepare medicaments for the prevention or treatment of various conditions and diseases described herein that are associated with CD318 expression.
  • Diseases or conditions refer to diseases caused directly or indirectly by abnormal expression of CD318, usually referring to diseases caused by overexpression of CD318, such as cancer, including but not limited to: breast cancer, lung cancer, liver cancer, pancreatic cancer, ovarian cancer , kidney cancer and colorectal cancer.
  • the invention also encompasses a type of cell therapy that involves expressing a CAR as described herein in immune cells (eg, T cells) and administering to a recipient in need thereof a therapeutically effective amount of the cells capable of killing tumor cells in the recipient.
  • immune cells eg, T cells
  • CAR-T cells are able to replicate in vivo, producing long-term persistence that can lead to sustained tumor control.
  • the anti-tumor immune response caused by CAR-T cells can be an active or passive immune response.
  • a CAR-mediated immune response can be part of an adoptive immunotherapy step, in which CAR-T cells induce an immune response specific for the antigen-binding portion of the CAR.
  • the antibodies, nucleic acids or CAR-modified cells of the invention can be administered alone or as pharmaceutical compositions in combination with diluents and/or with other components such as relevant cytokines or cell populations.
  • the pharmaceutical composition may be prepared in the form of a lyophilized preparation or aqueous solution by mixing the active agent with the desired purity and optionally a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers are nontoxic to the recipient at the dosage and concentration used and may include buffers (e.g., neutral buffered saline, sulfate buffered saline), antioxidants, preservatives, isotonic agents, stabilizing agents at least one of an agent, a chelating agent (such as EDTA or glutathione), an adjuvant (such as aluminum hydroxide), and a surfactant.
  • buffers e.g., neutral buffered saline, sulfate buffered saline
  • antioxidants e.g., sulfate buffered saline
  • preservatives e.g., isotonic agents
  • stabilizing agents at least one of an agent e.g., a chelating agent (such as EDTA or glutathione), an adjuvant (such as aluminum hydroxide), and a surfactant.
  • an adjuvant such as aluminum hydroxide
  • surfactant such as aluminum
  • compositions may contain at least one additive from the group consisting of cytotoxic agents, chemotherapeutic agents, cytokines, immunosuppressants, growth inhibitors, and active agents required for the particular indication to be treated.
  • the specific amount of additives can be adjusted according to actual needs.
  • the pharmaceutical composition of the present invention may be administered in an "immunologically effective amount", “anti-tumor effective amount”, “tumor-inhibitory effective amount” or "therapeutic amount”.
  • Treatment refers to a subject taking a treatment regimen described herein to achieve at least one positive therapeutic effect (for example, reduction in the number of cancer cells, reduction in tumor volume, reduction in the rate of cancer cell infiltration into surrounding organs, or reduction in tumor metastasis or tumor growth) rate decreases).
  • an "immunologically effective amount”, “anti-tumor effective amount”, “tumor-suppressive effective amount” or “therapeutic amount” is indicated, the precise amount of the composition of the invention to be administered can be determined by the physician, who takes into account the patient (subject) ) age, weight, tumor size, degree of infection or metastasis, and individual differences in disease.
  • compositions including T cells described herein may be administered at a dose of 10 4 to 10 9 cells/kg body weight, preferably 10 5 to 10 6 cells/kg body weight. T cell compositions can also be administered multiple times at these dosages. Cells can be administered using infusion techniques well known in immunotherapy (see, eg, Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dosage and treatment regimen for a particular patient can be readily determined by one skilled in the medical field by monitoring the patient for signs of disease and adjusting treatment accordingly.
  • compositions described herein can be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intraspinally, intramuscularly, by intravenous injection, or intraperitoneally.
  • the T cell composition of the invention is administered to the patient by intradermal or subcutaneous injection.
  • the T cell composition of the invention is preferably administered by intravenous injection.
  • the composition of T cells can be injected directly into the tumor, lymph node or site of infection.
  • the CAR-T cells of the invention or compositions thereof may be combined with other therapies known in the art.
  • described Therapies include, but are not limited to, chemotherapy, radiation therapy, and immunosuppressants.
  • treatment may be combined with radiotherapy or chemotherapy agents known in the art to treat CD318-mediated diseases.
  • anti-tumor effect refers to a biological effect, which can be expressed by a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms related to cancer.
  • Patient “Patient,” “subject,” “individual” and the like are used interchangeably herein to refer to a living organism, such as a mammal, that can elicit an immune response. Examples include, but are not limited to, humans, dogs, cats, mice, rats, and transgenic species thereof.
  • the binding molecules of the invention can be used in assays due to their high affinity for CD318, such as binding assays to detect and/or quantify CD318 expressed in tissues or cells. Binding molecules such as single domain antibodies can be used in studies to further investigate the role of CD318 in disease.
  • the method for detecting CD318 is roughly as follows: obtain cell and/or tissue samples; detect the level of CD318 in the samples.
  • the CD318-binding molecules of the invention may be used for diagnostic purposes to detect, diagnose or monitor CD318-related diseases and/or conditions.
  • the present invention provides for the detection of the presence of CD318 in a sample using classical immunohistological methods known to those skilled in the art. Detection of CD318 can be performed in vivo or in vitro. Examples of methods suitable for detecting the presence of CD318 include ELISA, FACS, RIA, etc.
  • binding molecules such as single domain antibodies are often labeled with detectable labeling groups.
  • Suitable labeling groups include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3H, 14C, 15N, 35S, 90Y, 99Tc, 111In, 125I, 131I), fluorescent groups (e.g., FITC, Rodan fluorophores, lanthanide phosphors), enzymatic groups (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), chemiluminescent groups, biotinyl groups or a predetermined polypeptide epitope recognized by a secondary reporter (e.g., leucine zipper pair sequence, binding site for secondary antibody, metal binding domain, epitope tag), MRI (magnetic resonance imaging) or CT (Computed X-ray tomography) contrast agent.
  • a secondary reporter e.
  • Another aspect of the invention provides a method of detecting the presence of a test molecule that competes with an antibody of the invention for binding to CD318.
  • An example of such an assay would involve detecting the amount of free antibody in a solution containing an amount of CD318 in the presence or absence of a test molecule.
  • An increased amount of free antibody i.e., antibody that does not bind CD318, will indicate that the test molecule is able to compete with the antibody for binding to CD318.
  • the antibody is labeled with a labeling group.
  • the test molecule is labeled and the amount of free test molecule is monitored in the presence or absence of antibody.
  • the invention also provides a detection kit for detecting CD318 levels.
  • the kit includes an antibody that recognizes CD318 protein, a lysis medium for dissolving the sample, and general reagents and buffers required for detection, such as various buffers, detection Labeling, detection substrate, etc.
  • the detection kit may be an in vitro diagnostic device.
  • Example 1 Construction and eukaryotic expression of recombinant human CD318 protein expression vector
  • a one-step method was used to construct a nanobody phage display library, that is, the alpaca nanobody VHH gene was connected to the phage display vector.
  • Alpaca immunization services are provided by Chengdu Apak Biotechnology Co., Ltd.
  • the specific operation process is as follows:
  • Alpaca selection Choose alpacas that are healthy, strong, in good spirits, and of moderate size. The selected alpacas have bright wool and no symptoms of injury or discomfort. Select good animals and raise them for about a week first to eliminate some unqualified animals so that later experiments can proceed smoothly.
  • Immunization plan B Select the alpaca and ensure that the animal is suitable. Record the ear number and start the immunity experiment. A total of 4 immunizations were performed.
  • the immunization plan is as follows: D0, take 10 mL of blood before immunization, and use it as a negative serum control. Mix 0.5 mg of antigen and 1 ml of CFA and then inject it subcutaneously; D21, mix 0.25 mg of antigen and 1 ml of CFA and inject it subcutaneously; D28, take 10 ml of blood.
  • D42 mix 0.25 mg of antigen and 1 ml of CFA and then inject subcutaneously
  • D49 collect 50 mL of peripheral blood to isolate lymphocytes
  • D63 mix 0.25 mg of antigen and 1 ml of CFA and inject subcutaneously
  • D70 collect 50 mL of peripheral blood to isolate lymphocytes.
  • Extract PBMC total RNA Dissolve peripheral blood lymphocytes preserved in Trizol on ice and transfer to a 1.5 mL centrifuge tube. Add 1/5 volume of chloroform and shake to mix, let stand at room temperature for 5 minutes, then centrifuge at 4°C at 12000g for 15 minutes; Transfer the centrifuged supernatant to a new centrifuge tube, add an equal volume of isopropanol to the new centrifuge tube, let it stand at room temperature for 10 minutes, then centrifuge at 12000g for 10 minutes at 4°C, wash the precipitate with 75% ethanol, 7500g at 4°C After centrifugation for 5 minutes, discard the supernatant, dry the pellet at room temperature and dissolve it in an appropriate amount of RNase-free water. Analyze RNA extraction purity from A260/280 and prepare for RNA transcription.
  • cDNA synthesis Use the SuperScript TM IV First-Strand Synthesis System kit to reverse-transcribe cDNA and store it at -80°C.
  • VHH-F forward primer
  • CH2-R reverse primer
  • the PCR reaction conditions are as follows: pre-denature at 98°C for 45 seconds and then enter the temperature cycle. Denaturation at 98°C for 15 seconds, annealing at 58°C for 20 seconds, extension at 72°C 45 seconds, 30 cycles, final extension at 72°C for 7 minutes. After the PCR product was subjected to 1.5% agarose gel electrophoresis, a gel recovery kit (Promega) was used to recover the 750 bp target band.
  • VHH-CH2-F forward primer
  • VHJ-R reverse primer
  • the PCR reaction conditions are as follows: pre-denature at 98°C for 45 seconds and then enter the temperature cycle, 98 Denaturation at °C for 15 seconds, annealing at 60°C for 20 seconds, extension at 72°C for 45 seconds, 30 cycles, and final extension at 72°C for 7 minutes. After the PCR product was electrophoresed on a 1.5% agarose gel, a 400 bp target band was recovered using a gel recovery kit (Promega).
  • the phagemid vector pcomb3X and VHH genes were digested with SfiI DNA endonuclease for 16 hours at 50°C.
  • the digested pcomb3X vector was subjected to 1% agarose gel electrophoresis and recovered using a gel recovery kit (Promega). 4000bp vector fragment.
  • the digested VHH gene was directly purified through the column using a gel recovery kit (400 bp).
  • the VHH gene was ligated into the phagemid vector using T4 DNA ligase kit (Invitrogen), and the ligation was carried out overnight at 16°C. A small amount of the ligation product was taken for agarose gel electrophoresis to detect the ligation efficiency.
  • the ligation product is desalted using MECK MILLIPOREF microporous filter membrane.
  • the above-mentioned ligation product was added to the self-made TG1 electroconversion competent cell, and then electroporation was performed using an electroporation instrument. Take out 50 ⁇ L of bacterial solution and perform gradient dilution 10 2 -10 5 times with PBS. Streamline 10 ⁇ L of each gradient dilution on an Amp/2YT plate and incubate at 37°C overnight to count and calculate the size of the phage antibody library. Add 2YT to the remaining electrotransformed bacteria to 500 ml, add ampicillin containing 100 ⁇ g/mL, and culture at 30°C and 220 rpm overnight. Finally, a VHH immune library exceeding 9E9 was obtained. The antibody library transformed by electroporation was amplified overnight, and the library cells were collected by centrifugation. The final concentration of 20% glycerol was added and stored at -80 degrees.
  • the avi-tag of the recombinant human CD318 protein was biotin-modified to obtain biotinylated CD318 protein.
  • Example 3 Preparation of retrovirus stock solution containing anti-human CD318 chimeric antigen receptor element
  • the chimeric antigen receptor sequence containing the single-domain antibody VHH, hinge region, transmembrane region and intracellular signal segment against human CD318 antigen is genetically synthesized or cloned. Its structure is shown in Figure 2. According to the different loaded VHHs, the chimeric antigen receptors are named 4A4-BBz, 4A8-BBz, 4A10-BBz, 4B2-BBz, 4B7-BBz, 4B12-BBz, 4F5-BBz, 4G2-BBz, and 4A4-BBz.
  • amino acid sequences of , 4A8-BBz, 4A10-BBz, 4B2-BBz, 4B7-BBz, and 4G2-BBz are shown in SEQ ID NO.30-35 respectively, and the nucleotide sequences are shown in SEQ ID NO.36 to SEQ respectively. Shown as ID NO.41.
  • chimeric antigen receptors expressing 4A4-BBz, 4A8-BBz, 4A10-BBz, 4B2-BBz, 4B7-BBz, 4B12-BBz, 4F5-BBz, and 4G2-BBz clones were constructed. of retroviral plasmids. Select the correctly sequenced clone, inoculate the bacterial solution into 200ml 2YT medium, shake the culture overnight, and follow the instructions of the NucleoBondXtra Maxi EF kit to complete the plasmid purification.
  • PEI cationic polymer
  • the process is as follows: dilute 36 ⁇ L PEI and retrovirus packaging plasmid (viral main plasmid 6 ⁇ g, Gag-pol 3.8 ⁇ g, vsvg 1.5 ⁇ g) with 600 ⁇ L serum-free DMEM respectively; then PEI/DMEM Add the plasmid/DMEM mixture, vortex to mix, and let stand at room temperature for 15 minutes; add the plasmid-PEI complex to the pre-plated 293T cells.
  • PBMC Receive a PBMC, verify that the patient's individual identification number is correct, and then perform resuscitation.
  • PBMC that had been recovered overnight were pipetted gently, filtered with a 70 ⁇ m cell mesh, transferred to a 50 ml centrifuge tube, centrifuged at room temperature, 1500 rpm, for 5 min, and the supernatant was discarded.
  • Remove the magnetic stand from the flow tube take an equal volume of DPBS or X-VIVO15 and resuspend the cell suspension, add the magnetic beads and cells in the cell suspension, mix in a 15ml centrifuge tube, and incubate on a rotating mixer. Incubate at room temperature for 30 minutes. After the incubation is completed, gently transfer the cells to a sterile flow tube, rinse the 15ml centrifuge tube with 1ml DPBS, and merge the rinse solution into the same flow tube. Move the sterile flow tube to the magnetic stand, let it stand for 1 minute, and then aspirate the unadsorbed liquid.
  • CAR-T culture medium to adjust the cell density to 1 ⁇ 10 6 ml, add IL-2 to a final concentration of 200IU/ml, and culture in a 37°C, 5% CO 2 incubator for two days.
  • Adjust the activated T cells to 5 ⁇ 10 5 /mL add 1 ml of T cells and 1 ml of virus stock solution to a 24-well plate, add 2 ⁇ L polybrene to each well, and centrifuge at 32°C, 2500 rpm for 1.5 h. Discard the supernatant and add 1 ml of T cell culture medium (containing IL-2 300IU/ml) to each well. Place the culture plate in a 37°C, 5% CO2 incubator. 24 hours after infection, transfer to a 6-well plate, observe the cell density every day, and add T cell culture medium containing IL-2 300IU/ml in a timely manner to maintain the density of T cells at about 1 ⁇ 10 6 /ml and allow the cells to expand. increase.
  • the positive rate of CAR was detected in retrovirus-infected T lymphocytes 72 hours after virus infection.
  • the chimeric antigen receptor group containing 4A4, 4A8, 4A10, 4B2, 4B7, 4B12, 4F5, and 4G2 clones and the negative uninfected control group NT take 1 ⁇ 10 6 cells respectively, centrifuge to remove the culture medium, and use 500 ⁇ L PBS Wash the cells once and resuspend them in 100 ⁇ L in a flow cytometry tube (BD). Biotin-labeled CD318 antigen (1:200) was added and incubated four times for 30 minutes.
  • Example 5 Functional analysis of CAR-T cells based on anti-human CD318
  • CAR-T cells containing different antibody clones were used with target cells (CD318-positive pancreatic cancer cell line BxPC3) and control target cells (CD318-negative human glioma cell U251) at a ratio of 1:1. After a total of 4 hours of incubation in a 37°C, 5% CO 2 incubator, the proportion of cells expressing CD107a in each group of samples that were positive for CAR-T was measured by flow cytometry. Cell number ratio. Evaluate the degranulation response of CAR-T cells after stimulation by target cells. The results of flow cytometry analysis of CD107a expression are shown in Figure 4.
  • CAR-T cells containing different antibody clones were compared with target cells (CD318-positive cell line BxPC3) and control target cells (CD318-negative cell line U251) at an effect-to-target ratio of 10:1 and 2:1 respectively.
  • target cells CD318-positive cell line BxPC3
  • control target cells CD318-negative cell line U251
  • Target cells are 3 ⁇ 10 4
  • the supernatant was collected, and the secretion of IFN- ⁇ and IL-2 was detected using ELISA (enzyme-linked immunoassay) method.
  • IFN- ⁇ and IL-2 were detected using the Human IFN-gamma ELISA Kit, Human IL-2ELISA kit, and the experimental steps were performed according to the product instructions.
  • the detection results of IFN- ⁇ secretion are shown in Figure 5 and Figure 6.
  • the detection results of IL-2 secretion are shown in Figure 7 and Figure 8.
  • the CAR-T killing toxicity experiment evaluates the in vitro function of CAR-T cells by detecting the killing effect of CAR-T cells on target cells in vitro.
  • the T cells were treated with CD318-positive target cells stably expressing firefly luciferase BxPC3-LUC- at different effective-to-target ratios (based on 3 ⁇ 10 4 target cells, the effective-to-target ratios were 10:1 and 2:1 respectively).
  • GFP, and CD318 negative control target cells U251-LUC-GFP were co-cultured, and a positive control with only target cells was set up.
  • Killing efficiency (fluorescence value of positive control well - fluorescence value of experimental well)/fluorescence of positive control well value) ⁇ 100%.

Abstract

La présente invention concerne un anticorps VHH qui se lie spécifiquement à CD318 humain ou à un fragment de liaison à l'antigène de celui-ci, son procédé de préparation et son utilisation. L'invention concerne une molécule de liaison à CD318 comprenant un nano-anticorps anti-CD318 ou un fragment de liaison à l'antigène de celui-ci. L'invention concerne en outre un récepteur antigénique chimérique comprenant la molécule de liaison à CD318 et une cellule d'expression de celui-ci. L'anticorps et la cellule décrits dans la présente demande ont de bons effets thérapeutiques dans le ciblage de CD318.
PCT/CN2023/099572 2022-06-14 2023-06-12 Anticorps vhh se liant spécifiquement à cd318 humain ou son fragment de liaison à l'antigène, son procédé de préparation et son utilisation WO2023241492A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210664867.1A CN117264055A (zh) 2022-06-14 2022-06-14 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
CN202210664867.1 2022-06-14

Publications (1)

Publication Number Publication Date
WO2023241492A1 true WO2023241492A1 (fr) 2023-12-21

Family

ID=89192208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/099572 WO2023241492A1 (fr) 2022-06-14 2023-06-12 Anticorps vhh se liant spécifiquement à cd318 humain ou son fragment de liaison à l'antigène, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN117264055A (fr)
WO (1) WO2023241492A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482357A (zh) * 2009-08-28 2012-05-30 罗切格利卡特公司 人源化抗cdcp1抗体
WO2021132427A1 (fr) * 2019-12-27 2021-07-01 株式会社カイオム・バイオサイエンス Anticorps anti-cdcp1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482357A (zh) * 2009-08-28 2012-05-30 罗切格利卡特公司 人源化抗cdcp1抗体
WO2021132427A1 (fr) * 2019-12-27 2021-07-01 株式会社カイオム・バイオサイエンス Anticorps anti-cdcp1

Also Published As

Publication number Publication date
CN117264055A (zh) 2023-12-22

Similar Documents

Publication Publication Date Title
US11897967B2 (en) Humanized anti-MUC1* antibodies
CN110950953B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
TW201922784A (zh) ４﹘１ｂｂ抗體及其製備方法和應用
JP2021519610A (ja) 多価抗体
CN111560072B (zh) 抗人msln抗体以及靶向msln的免疫效应细胞
CN111848809A (zh) 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
WO2021043169A1 (fr) Anticorps se liant de manière spécifique à un antigène de maturation des lymphocytes b et son utilisation
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
WO2020038397A1 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
WO2024046239A1 (fr) Anticorps monoclonal humanisé recombinant ciblant gprc5d humain et son utilisation
WO2024002252A1 (fr) Nanocorps anti-trop2 et son utilisation
EP4269442A1 (fr) Molécule de liaison à la mésothéline et son utilisation
JP2022079486A (ja) 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体
KR20220066090A (ko) 마우스 및 인간 섬유아세포 활성화 단백질(fap)과 교차 반응하는 개과 섬유아세포 활성화 단백질에 대한 모노클로날 항체
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用
WO2023241492A1 (fr) Anticorps vhh se liant spécifiquement à cd318 humain ou son fragment de liaison à l'antigène, son procédé de préparation et son utilisation
KR20240014058A (ko) 항-cea 항체 및 항-cd137 다중 특이적 항체 및 사용 방법
WO2023241493A1 (fr) Anticorps se liant spécifiquement à trop2 ou à son fragment de liaison à l'antigène, son procédé de préparation et son utilisation
WO2023137958A1 (fr) Nanoanticorps anti-cd70 et son utilisation
TW202112813A (zh) 對lif具有專一性的結合分子及其用途
CN112225811A (zh) 新型抗人msln抗体及其用途
CN112210008A (zh) 一种新型抗人msln抗体及其用途
WO2022063100A1 (fr) Anticorps anti-tigit et anticorps double et leur application
WO2022242682A1 (fr) Anticorps multispécifiques anti-gpc3 et anti-cd137 et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23823060

Country of ref document: EP

Kind code of ref document: A1